慢性乙型肝炎抗病毒治疗进展(4)
[6]Wu X，Xin Z，Zhu X，et al.Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese[J].Antiviral Res，2012，93(2)：297-300.
[7]Sonneveld MJ，Wong VW，Woltman AM，et al.Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic Hepatitis B[J].Gastroenterology，2012，142(3)：513-520.
[8]Lampertico P，Vigano M，Cheroni C，et al.IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B[J].Hepatology，2013，57(3)：890-896.
, 百拇医药
[9]朱月永，吳银莲，陈靖，等.聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎72周疗程的疗效优于常规疗程[J].中华肝脏病杂志，2012，20(10)：737-741.
[10]曹振环，马丽娜，柳雅立，等.聚乙二醇干扰素α-2a联合阿德福韦酯治疗HBeAg阴性慢性乙型肝炎的临床研究[J].中华肝脏病杂志，2013，21(7)：498-501.
[11]Lampertico P，Viganò M，Di Costanzo GG，et al.Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B[J].Gut，2013，62(2)：290-298.
[12]Liaw YF，Jia JD，Chan HL，et al.Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotype B or C[J].Hepatology，2011，54(5)：1591-1599.
, http://www.100md.com
[13]Rijckborst V，Hansen BE，Ferenci P，et al.Validation of a stopping rule at week12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alpha-2a[J].J Hepatol，2012，56(5)：1006-1011.
[14]Piratvisuth T，Marcellin P，Popescu M，et al.Hepatitis B surface antigen： association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients[J].Hepatol Int，2013，7(2)：429-436.
[15]Marcellin P，Bonino F，Yurdaydin C，et al.Hepatitis B surface antigen levels： association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients[J].Hepatol Int，2013，7(1)：88-97.
, http://www.100md.com
[16]Sonneveld MJ，Hansen BE，Piratvisuth T，et al.Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels[J].Hepatology，2013，58(3)：872-880.
[17]Ono A，Suzuki F，Kawamura Y，et al.Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients[J].J Hepatol，2012，57(3)：508-514.
[18]Hou JL，Jia JD，Wei L，et al.Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a 'real-world' clinical practice setting in China[J].J Viral Hepat，2013，20(11)：811-820., 百拇医药(汪晓凤 邵和军)
[7]Sonneveld MJ，Wong VW，Woltman AM，et al.Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic Hepatitis B[J].Gastroenterology，2012，142(3)：513-520.
[8]Lampertico P，Vigano M，Cheroni C，et al.IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B[J].Hepatology，2013，57(3)：890-896.
, 百拇医药
[9]朱月永，吳银莲，陈靖，等.聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎72周疗程的疗效优于常规疗程[J].中华肝脏病杂志，2012，20(10)：737-741.
[10]曹振环，马丽娜，柳雅立，等.聚乙二醇干扰素α-2a联合阿德福韦酯治疗HBeAg阴性慢性乙型肝炎的临床研究[J].中华肝脏病杂志，2013，21(7)：498-501.
[11]Lampertico P，Viganò M，Di Costanzo GG，et al.Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B[J].Gut，2013，62(2)：290-298.
[12]Liaw YF，Jia JD，Chan HL，et al.Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotype B or C[J].Hepatology，2011，54(5)：1591-1599.
, http://www.100md.com
[13]Rijckborst V，Hansen BE，Ferenci P，et al.Validation of a stopping rule at week12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alpha-2a[J].J Hepatol，2012，56(5)：1006-1011.
[14]Piratvisuth T，Marcellin P，Popescu M，et al.Hepatitis B surface antigen： association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients[J].Hepatol Int，2013，7(2)：429-436.
[15]Marcellin P，Bonino F，Yurdaydin C，et al.Hepatitis B surface antigen levels： association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients[J].Hepatol Int，2013，7(1)：88-97.
, http://www.100md.com
[16]Sonneveld MJ，Hansen BE，Piratvisuth T，et al.Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels[J].Hepatology，2013，58(3)：872-880.
[17]Ono A，Suzuki F，Kawamura Y，et al.Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients[J].J Hepatol，2012，57(3)：508-514.
[18]Hou JL，Jia JD，Wei L，et al.Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a 'real-world' clinical practice setting in China[J].J Viral Hepat，2013，20(11)：811-820., 百拇医药(汪晓凤 邵和军)